O-(4-iodobenzyl)hydroxylamine | 1160488-00-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: O-(4-iodobenzyl)hydroxylamine
• 英文别名: O-[(4-iodophenyl)methyl]hydroxylamine
• CAS: 1160488-00-5
• 化学式: C₇H₈INO
• 分子量: 249.051
• InChiKey: RADNEVOWMRVABV-UHFFFAOYSA-N

物化性质

• 沸点：
  304.6±25.0 °C(Predicted)
• 密度：
  1.806±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  O-(4-iodobenzyl)hydroxylamine 在 盐酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 O-(4-iodobenzyl)hydroxylamine hydrochloride
  参考文献：
  名称：

  4-Alkyloxyimino-cytosine nucleotides: tethering approaches to molecular probes for the P2Y6 receptor

  摘要：

  4-烷氧亚氨基嘧啶核苷酸衍生物作为某些G蛋白偶联P2Y受体（P2YRs）的激动剂显示出高度效力。为了对P2Y6R激动剂进行荧光标记，我们在两个位置（胞苷衍生物的N4位和γ-磷酸基团）上探查了包括炔烃在内的各种功能团，用于点击化学反应。在CDP的嘧啶核碱4位上进行扩展亚氨基取代，相比于CTP衍生物中的γ-磷酸酯形成，通常更好地保持了P2Y6R的效力。荧光染料Alexa Fluor 488的共轭物16激活了在1321N1人星形胶质瘤细胞中表达的人P2Y6R，其EC50为9 nM，并且对这种受体的选择性远高于其他由尿嘧啶核苷酸激活的P2Y受体。流式细胞术检测到16对表达P2Y6R的细胞有特异性标记，而对野生型1321N1细胞无标记。此外，共聚焦显微镜显示16被内化（半衰期18分钟）并有表面结合的荧光。已知的P2Y6R配体抑制标记。16与P2Y6R的同源模型的理论对接预测了荧光团与TM3的外部部分之间的静电相互作用。因此，我们确定了N4-苄氧基团作为合成功能化类似物的结构容许位点，从而得到用于研究P2Y6R的高亲和力分子探针。

  DOI：

  10.1039/c3md00132f
• 作为产物：
  描述：

  4-碘苄醇 在 偶氮二甲酸二异丙酯 、 一水合肼 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 生成 O-(4-iodobenzyl)hydroxylamine
  参考文献：
  名称：

  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1

  摘要：

  Indoleamine 2,3-dioxygenase-1 (IDO1) is a promising therapeutic target for the treatment of cancer, chronic viral infections, and other diseases characterized by pathological immune suppression. Recently important advances have been made in understanding IDO1's catalytic mechanism. Although much remains to be discovered, there is strong evidence that the mechanism proceeds through a heme-iron bound alkylperoxy transition or intermediate state. Accordingly, we explored stable structural mimics of the alkylperoxy species and provide evidence that such structures do mimic the alkylperoxy transition or intermediate state. We discovered that O-benzylhydroxylamine, a commercially available compound, is a. potent sub-micromolar inhibitor of IDO1. Structure activity studies of over forty derivatives of O-benzylhydroxylamine led to further improvement in inhibitor potency, particularly with the addition of halogen atoms to the meta position of the aromatic ring. The most potent derivatives and the lead, O-benzylhydroxylamine, have high ligand efficiency values, which are considered an important criterion for successful drug development. Notably, two of the most potent compounds demonstrated nanomolar-level cell-based potency and limited toxicity. The combination of the simplicity of the structures of these compounds and their excellent cellular activity makes them quite attractive for biological exploration of IDO1 function and antitumor therapeutic applications. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.12.028

文献信息

• 4-Alkyloxyimino-cytosine nucleotides: tethering approaches to molecular probes for the P2Y6 receptor
  作者：P. Suresh Jayasekara、Matthew O. Barrett、Christopher B. Ball、Kyle A. Brown、Eszter Kozma、Stefano Costanzi、Lucia Squarcialupi、Ramachandran Balasubramanian、Hiroshi Maruoka、Kenneth A. Jacobson

  DOI：10.1039/c3md00132f

  日期：——

  4-Alkyloxyimino derivatives of pyrimidine nucleotides display high potency as agonists of certain G protein-coupled P2Y receptors (P2YRs). In an effort to functionalize a P2Y6R agonist for fluorescent labeling, we probed two positions (N4 and γ-phosphate of cytidine derivatives) with various functional groups, including alkynes for click chemistry. Functionalization of extended imino substituents at the 4 position of the pyrimidine nucleobase of CDP preserved P2Y6R potency generally better than γ-phosphoester formation in CTP derivatives. Fluorescent Alexa Fluor 488 conjugate 16 activated the human P2Y6R expressed in 1321N1 human astrocytoma cells with an EC50 of 9 nM, and exhibited high selectivity for this receptor over other uridine nucleotide-activated P2Y receptors. Flow cytometry detected specific labeling with 16 to P2Y6R-expressing but not to wild-type 1321N1 cells. Additionally, confocal microscopy indicated both internalized 16 (t1/2 of 18 min) and surface-bound fluorescence. Known P2Y6R ligands inhibited labeling. Theoretical docking of 16 to a homology model of the P2Y6R predicted electrostatic interactions between the fluorophore and extracellular portion of TM3. Thus, we have identified the N4-benzyloxy group as a structurally permissive site for synthesis of functionalized congeners leading to high affinity molecular probes for studying the P2Y6R.

  4-烷氧亚氨基嘧啶核苷酸衍生物作为某些G蛋白偶联P2Y受体（P2YRs）的激动剂显示出高度效力。为了对P2Y6R激动剂进行荧光标记，我们在两个位置（胞苷衍生物的N4位和γ-磷酸基团）上探查了包括炔烃在内的各种功能团，用于点击化学反应。在CDP的嘧啶核碱4位上进行扩展亚氨基取代，相比于CTP衍生物中的γ-磷酸酯形成，通常更好地保持了P2Y6R的效力。荧光染料Alexa Fluor 488的共轭物16激活了在1321N1人星形胶质瘤细胞中表达的人P2Y6R，其EC50为9 nM，并且对这种受体的选择性远高于其他由尿嘧啶核苷酸激活的P2Y受体。流式细胞术检测到16对表达P2Y6R的细胞有特异性标记，而对野生型1321N1细胞无标记。此外，共聚焦显微镜显示16被内化（半衰期18分钟）并有表面结合的荧光。已知的P2Y6R配体抑制标记。16与P2Y6R的同源模型的理论对接预测了荧光团与TM3的外部部分之间的静电相互作用。因此，我们确定了N4-苄氧基团作为合成功能化类似物的结构容许位点，从而得到用于研究P2Y6R的高亲和力分子探针。
• NOVEL VASCULAR LEAKAGEAGE INHIBITOR
  申请人：Industry-Academic Cooperation Foundation, Yonsei University

  公开号：US20140378399A1

  公开（公告）日：2014-12-25

  The present disclosure relates to a novel vascular leakage inhibitor. The novel vascular leakage inhibitor of the present invention inhibits the apoptosis of vascular endothelial cells, inhibits the formation of actin stress fibers induced by VEGF, and enhances the cortical actin ring structure, thereby inhibiting vascular leakage. Accordingly, the vascular leakage inhibitor of the present invention can prevent or treat various diseases caused by vascular leakage. Since the vascular leakage inhibitor of the present invention is synthesized from commercially available or easily synthesizable pregnenolones, it has remarkably superior feasibility of commercial synthesis.

  本公开涉及一种新型血管渗漏抑制剂。本发明的新型血管渗漏抑制剂抑制血管内皮细胞凋亡，抑制由VEGF诱导的肌动蛋白应激纤维的形成，并增强皮质肌动蛋白环结构，从而抑制血管渗漏。因此，本发明的血管渗漏抑制剂可以预防或治疗由血管渗漏引起的各种疾病。由于本发明的血管渗漏抑制剂是由商业可获得或易于合成的孕酮合成的，因此具有明显优越的商业合成可行性。
• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。
• Design, Synthesis, and Biological Evaluation of Novel Constrained <i>meta</i>-Substituted Phenyl Propanoic Acids as Peroxisome Proliferator-Activated Receptor α and γ Dual Agonists
  作者：Young-Ger Suh、Nam-Jung Kim、Bon-Woong Koo、Kwang-Ok Lee、Sung-Hyun Moon、Dong-Hyung Shin、Jong-Wha Jung、Seung-Mann Paek、Dong-Jo Chang、Funan Li、Hyun-Jin Kang、Tuong Vy Thi Le、Yu Na Chae、Chang Yell Shin、Mi-Kyung Kim、Joong In Lim、Jae-Sang Ryu、Hyun-Ju Park

  DOI：10.1021/jm8003416

  日期：2008.10.23

  In an effort to develop dual PPAR alpha/gamma activators with improved therapeutic efficacy, a series of diaryl alpha-ethoxy propanoic acid compounds comprising two aryl groups linked by rigid oxime ether or isoxazoline ring were designed and synthesized and their biological activities were examined. Most of the compounds possessing an oxime ether linker were more potent PPAR gamma activators than the lead PPAR alpha/gamma dual agonist, tesaglitazar in vitro. Compound 18, one of the derivatives with an oxime ether linker, was found to selectively transactivate PPAR gamma (EC(50) = 0.028 mu M) over PPAR alpha (EC(50) = 7.22 mu M) in vitro and lower blood glucose in db/db mice more than muraglitazar after oral treatment for 11 days.
• IDO INHIBITORS
  申请人：Newlink Genetics

  公开号：EP2227233A2

  公开（公告）日：2010-09-15